Basic and translational research has investigated the role of nm23 in the regulation of tumor metastasis. Five transfection studies have documented that overexpression of nm23 cDNA in either breast carcinoma or melanoma cell lines results in a 50-90% decrease in tumor metastatic potential in vivo. The biochemical mechanism whereby Nm23 suppresses metastatic potential is under investigation. We have transfected site directed mutants of nm23-H1 into breast carcinoma cell lines and examined their in vitro motility to correlate Nm23 structure and biological function. Two mutations abrogated the tumor cell motility suppressive capacity of Nm23:proline 96, the killer of prune mutation in the Drosophila nm23 homolog, which can cause aberrant differentiation; serine 120, a site of mutation in human Stage IV neuroblastomas, and phosphorylation. We have subsequently expressed and purified each Nm23 mutant protein, and tested them for biochemical activities in vitro. We found that the proline 96 and serine 120 mutant proteins were uniquely deficient in aspects of histidine-dependent protein phosphotransferase pathways, and have hypothesized that this biochemical pathway may be responsible for the biological suppressive effects of Nm23. Two translational projects are underway: We have identified the promoter for nm23-H1, and the portion which determines whether breast carcinoma cell lines of varying metastatic potentials express high or low Nm23 levels. No mutations were detected in this region. Talks are underway with a pharmaceutical company to use the nm23-H1 promoter to screen for drugs which will elevate cellular Nm23 expression. Using the COMPARE computer program in collaboration with DTP, we have used Nm23 as a marker to identify novel compounds with preferential in vitro inhibitory activity against the most aggressive human breast and melanoma cell lines. One of these compounds, NSC680718, has in vivo activity in the hollow fiber assay and has been referred by the BEC for xenograft testing.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Intramural Research (Z01)
Project #
1Z01SC000892-13
Application #
2464425
Study Section
Special Emphasis Panel (LP)
Project Start
Project End
Budget Start
Budget End
Support Year
13
Fiscal Year
1996
Total Cost
Indirect Cost
Name
National Cancer Institute Division of Clinical Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Marino, Natascia; Collins, Joshua W; Shen, Changyu et al. (2014) Identification and validation of genes with expression patterns inverse to multiple metastasis suppressor genes in breast cancer cell lines. Clin Exp Metastasis 31:771-86
Steeg, Patricia S; Anderson, Robin L; Bar-Eli, Menashe et al. (2009) An open letter to the FDA and other regulatory agencies: Preclinical drug development must consider the impact on metastasis. Clin Cancer Res 15:4529
Lu, Jing; Steeg, Patricia S; Price, Janet E et al. (2009) Breast cancer metastasis: challenges and opportunities. Cancer Res 69:4951-3
Horak, Christine E; Lee, Jong Heun; Elkahloun, Abdel G et al. (2007) Nm23-H1 suppresses tumor cell motility by down-regulating the lysophosphatidic acid receptor EDG2. Cancer Res 67:7238-46
Athauda, Gagani; Giubellino, Alessio; Coleman, Jonathan A et al. (2006) c-Met ectodomain shedding rate correlates with malignant potential. Clin Cancer Res 12:4154-62
Palmieri, Diane; Horak, Christine E; Lee, Jong-Heun et al. (2006) Translational approaches using metastasis suppressor genes. J Bioenerg Biomembr 38:151-61
Steeg, Patricia S (2006) Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 12:895-904
Salerno, Massimiliano; Palmieri, Diane; Bouadis, Amina et al. (2005) Nm23-H1 metastasis suppressor expression level influences the binding properties, stability, and function of the kinase suppressor of Ras1 (KSR1) Erk scaffold in breast carcinoma cells. Mol Cell Biol 25:1379-88
Steeg, Patricia S (2005) New insights into the tumor metastatic process revealed by gene expression profiling. Am J Pathol 166:1291-4
Palmieri, Diane; Halverson, Douglas O; Ouatas, Taoufik et al. (2005) Medroxyprogesterone acetate elevation of Nm23-H1 metastasis suppressor expression in hormone receptor-negative breast cancer. J Natl Cancer Inst 97:632-42

Showing the most recent 10 out of 19 publications